Experts Highlight AI's Crucial Role in Transforming Drug Discovery
Synopsis
Discover how AI is set to revolutionize drug discovery and healthcare innovation. Experts discuss the future of pharmaceuticals during the India Pharma 2026 conference, emphasizing the need for a reimagined approach to R&D and regulatory frameworks.
Key Takeaways
AI accelerates drug discovery , enabling precision medicine.
Industry leaders call for a reimagined approach to R&D .
Strengthening regulatory frameworks is essential for global alignment.
Collaboration between industry and academia is crucial for innovation.
India's CRDMO sector is expanding rapidly, driven by outsourcing demand.
New Delhi, April 14 (NationPress) Experts assert that artificial intelligence will significantly expedite the process of drug discovery, pave the way for precision medicine, and cultivate a more intelligent, innovation-driven healthcare landscape.
Pharmaceutical leaders stressed the importance of rethinking existing workflows instead of simply digitizing them. They underscored the critical need for robust data and technological underpinnings to facilitate widespread AI integration, while also highlighting the immediate advantages of automation in enhancing clinical operations.
The opening day of the 9th ‘India Pharma 2026’ featured four influential plenary discussions that united policymakers, industry executives, regulators, and technology specialists to outline the future trajectory of India's pharmaceutical and life sciences sector.
The first plenary session emphasized the pressing urgency to align policy intentions with real-world implementations.
Manoj Joshi, Secretary of the Department of Pharmaceuticals, advocated for an industry-driven model in Research and Development, the necessity of fortifying government laboratory networks, and adjusting regulatory frameworks to align with European standards.
Rajiv Bahl, Secretary of the Department of Health Research, pointed out that while research funding has surged in recent years, India requires a Bharat model for R&D that fosters market confidence in innovators and enhances collaboration between industry and academia.
According to the Ministry of Chemicals and Fertilisers, industry leaders echoed the call for increased venture capital involvement and co-funding strategies to support research-oriented businesses, improved industry-academia collaboration, and highlighted the significance of integrated ecosystems to transform early-stage discoveries into global solutions.
The second plenary session concentrated on establishing a predictable, efficient, and globally harmonized regulatory framework.
Dr. Rajeev Singh Raghuvanshi, the Drug Controller General of India, stressed the importance of engaging stakeholders in the development of responsive regulatory frameworks.
The third plenary session delved into the groundbreaking potential of artificial intelligence across the pharmaceutical value chain.
The fourth session spotlighted India's expanding influence in the global Contract Research, Development, and Manufacturing Organization (CRDMO) arena.
The panel observed that India's CRDMO sector, currently valued at approximately $8 billion, is experiencing a robust growth rate of 10–12%, driven by strong global outsourcing demand.
Point of View
It's clear that the integration of artificial intelligence in drug discovery is no longer a distant dream but a rapidly approaching reality. The discussions at India Pharma 2026 underline the urgency for policy alignment and industry collaboration to leverage this technology for better healthcare outcomes.
NationPress
1 May 2026
Frequently Asked Questions
How is AI impacting drug discovery?
AI accelerates drug discovery by analyzing vast datasets, identifying potential drug candidates, and optimizing clinical trials, ultimately leading to faster and more precise therapies.
What is the significance of the Bharat model for R&D?
The Bharat model aims to create a supportive ecosystem for research and development in India, fostering trust between industry and academia and enhancing market confidence in innovators.
What challenges does the pharmaceutical industry face?
The industry faces challenges such as the need for robust regulatory frameworks, integration of technology, and increased funding for research-driven enterprises.
What role do stakeholders play in regulatory frameworks?
Stakeholders are crucial in shaping responsive regulatory systems that ensure safety and efficacy while promoting innovation in the pharmaceutical sector.
How is India's CRDMO sector performing?
India's CRDMO sector is valued at around $8 billion and is growing at a rate of 10–12%, reflecting strong global demand for outsourcing in drug development and manufacturing.
